Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells

Chew Yee Ngan, Hirofumi Yamamoto, Akimitsu Takagi, Yujiro Fujie, Ichiro Takemasa, Masataka Ikeda, Fumi Takahashi-Yanaga, Toshiyuki Sasaguri, Mitsugu Sekimoto, Nariaki Matsuura, Morito Monden

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The platinum-based chemotherapeutic agent oxaliplatin displays a wide range of antitumor activities. However, the underlying molecular responses to oxaliplatin in esophageal cancer remain largely unknown. In the present study, we investigated the effect of oxaliplatin on two esophageal cancer cell lines, squamous cell carcinoma (TE3) and adenocarcinoma (TE7). Following cell-cycle arrest at G2 phase after oxaliplatin treatment, TE3 cells died via apoptosis and TE7 cells died via mitotic catastrophe. Survivin was inhibited more in TE7 cells compared with TE3 cells, but inhibition of survivin using small interfering RNA induced mitotic catastrophe in both cell lines. Further investigations indicated that survivin promoter activity was also inhibited by oxaliplatin. Among mitotic catastrophe-associated proteins, 14-3-3σ was decreased in TE7 cells; no evident changes were observed for aurora kinases. Oxaliplatin-induced apoptosis in the TE3 cells was caspase dependent. However, downregulation of Bad, Bid, Puma, and Noxa, lack of cytochrome c release, and limited loss of mitochondrial membrane potential in early phase indicated possible initiation by pathways other than the mitochondrial pathway. Mechanistic studies showed that downregulation of survivin by oxaliplatin in TE7 cells was partially due to the proteasome-mediated protein degradation pathway and partially due to the downregulation of Sp1 transcription factor. Similar results were obtained for another gastric adenocarcinoma cell line, MKN45, in which survivin was previously shown to be inhibited by oxaliplatin. These data indicate that survivin may be a key target for oxaliplatin. The ability of oxaliplatin to induce different modes of cell death may contribute to its efficacy in esophageal cancer.

Original languageEnglish
Pages (from-to)129-139
Number of pages11
JournalCancer Science
Volume99
Issue number1
DOIs
Publication statusPublished - Jan 1 2008

Fingerprint

oxaliplatin
Esophageal Neoplasms
Apoptosis
Down-Regulation
Cell Line
Adenocarcinoma
Aurora Kinases
Puma
Noxae
Sp1 Transcription Factor
14-3-3 Proteins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Ngan, C. Y., Yamamoto, H., Takagi, A., Fujie, Y., Takemasa, I., Ikeda, M., ... Monden, M. (2008). Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Cancer Science, 99(1), 129-139. https://doi.org/10.1111/j.1349-7006.2007.00637.x

Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. / Ngan, Chew Yee; Yamamoto, Hirofumi; Takagi, Akimitsu; Fujie, Yujiro; Takemasa, Ichiro; Ikeda, Masataka; Takahashi-Yanaga, Fumi; Sasaguri, Toshiyuki; Sekimoto, Mitsugu; Matsuura, Nariaki; Monden, Morito.

In: Cancer Science, Vol. 99, No. 1, 01.01.2008, p. 129-139.

Research output: Contribution to journalArticle

Ngan, CY, Yamamoto, H, Takagi, A, Fujie, Y, Takemasa, I, Ikeda, M, Takahashi-Yanaga, F, Sasaguri, T, Sekimoto, M, Matsuura, N & Monden, M 2008, 'Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells', Cancer Science, vol. 99, no. 1, pp. 129-139. https://doi.org/10.1111/j.1349-7006.2007.00637.x
Ngan CY, Yamamoto H, Takagi A, Fujie Y, Takemasa I, Ikeda M et al. Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Cancer Science. 2008 Jan 1;99(1):129-139. https://doi.org/10.1111/j.1349-7006.2007.00637.x
Ngan, Chew Yee ; Yamamoto, Hirofumi ; Takagi, Akimitsu ; Fujie, Yujiro ; Takemasa, Ichiro ; Ikeda, Masataka ; Takahashi-Yanaga, Fumi ; Sasaguri, Toshiyuki ; Sekimoto, Mitsugu ; Matsuura, Nariaki ; Monden, Morito. / Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. In: Cancer Science. 2008 ; Vol. 99, No. 1. pp. 129-139.
@article{80ce28b6913e484bad39c7d31c80b42a,
title = "Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells",
abstract = "The platinum-based chemotherapeutic agent oxaliplatin displays a wide range of antitumor activities. However, the underlying molecular responses to oxaliplatin in esophageal cancer remain largely unknown. In the present study, we investigated the effect of oxaliplatin on two esophageal cancer cell lines, squamous cell carcinoma (TE3) and adenocarcinoma (TE7). Following cell-cycle arrest at G2 phase after oxaliplatin treatment, TE3 cells died via apoptosis and TE7 cells died via mitotic catastrophe. Survivin was inhibited more in TE7 cells compared with TE3 cells, but inhibition of survivin using small interfering RNA induced mitotic catastrophe in both cell lines. Further investigations indicated that survivin promoter activity was also inhibited by oxaliplatin. Among mitotic catastrophe-associated proteins, 14-3-3σ was decreased in TE7 cells; no evident changes were observed for aurora kinases. Oxaliplatin-induced apoptosis in the TE3 cells was caspase dependent. However, downregulation of Bad, Bid, Puma, and Noxa, lack of cytochrome c release, and limited loss of mitochondrial membrane potential in early phase indicated possible initiation by pathways other than the mitochondrial pathway. Mechanistic studies showed that downregulation of survivin by oxaliplatin in TE7 cells was partially due to the proteasome-mediated protein degradation pathway and partially due to the downregulation of Sp1 transcription factor. Similar results were obtained for another gastric adenocarcinoma cell line, MKN45, in which survivin was previously shown to be inhibited by oxaliplatin. These data indicate that survivin may be a key target for oxaliplatin. The ability of oxaliplatin to induce different modes of cell death may contribute to its efficacy in esophageal cancer.",
author = "Ngan, {Chew Yee} and Hirofumi Yamamoto and Akimitsu Takagi and Yujiro Fujie and Ichiro Takemasa and Masataka Ikeda and Fumi Takahashi-Yanaga and Toshiyuki Sasaguri and Mitsugu Sekimoto and Nariaki Matsuura and Morito Monden",
year = "2008",
month = "1",
day = "1",
doi = "10.1111/j.1349-7006.2007.00637.x",
language = "English",
volume = "99",
pages = "129--139",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells

AU - Ngan, Chew Yee

AU - Yamamoto, Hirofumi

AU - Takagi, Akimitsu

AU - Fujie, Yujiro

AU - Takemasa, Ichiro

AU - Ikeda, Masataka

AU - Takahashi-Yanaga, Fumi

AU - Sasaguri, Toshiyuki

AU - Sekimoto, Mitsugu

AU - Matsuura, Nariaki

AU - Monden, Morito

PY - 2008/1/1

Y1 - 2008/1/1

N2 - The platinum-based chemotherapeutic agent oxaliplatin displays a wide range of antitumor activities. However, the underlying molecular responses to oxaliplatin in esophageal cancer remain largely unknown. In the present study, we investigated the effect of oxaliplatin on two esophageal cancer cell lines, squamous cell carcinoma (TE3) and adenocarcinoma (TE7). Following cell-cycle arrest at G2 phase after oxaliplatin treatment, TE3 cells died via apoptosis and TE7 cells died via mitotic catastrophe. Survivin was inhibited more in TE7 cells compared with TE3 cells, but inhibition of survivin using small interfering RNA induced mitotic catastrophe in both cell lines. Further investigations indicated that survivin promoter activity was also inhibited by oxaliplatin. Among mitotic catastrophe-associated proteins, 14-3-3σ was decreased in TE7 cells; no evident changes were observed for aurora kinases. Oxaliplatin-induced apoptosis in the TE3 cells was caspase dependent. However, downregulation of Bad, Bid, Puma, and Noxa, lack of cytochrome c release, and limited loss of mitochondrial membrane potential in early phase indicated possible initiation by pathways other than the mitochondrial pathway. Mechanistic studies showed that downregulation of survivin by oxaliplatin in TE7 cells was partially due to the proteasome-mediated protein degradation pathway and partially due to the downregulation of Sp1 transcription factor. Similar results were obtained for another gastric adenocarcinoma cell line, MKN45, in which survivin was previously shown to be inhibited by oxaliplatin. These data indicate that survivin may be a key target for oxaliplatin. The ability of oxaliplatin to induce different modes of cell death may contribute to its efficacy in esophageal cancer.

AB - The platinum-based chemotherapeutic agent oxaliplatin displays a wide range of antitumor activities. However, the underlying molecular responses to oxaliplatin in esophageal cancer remain largely unknown. In the present study, we investigated the effect of oxaliplatin on two esophageal cancer cell lines, squamous cell carcinoma (TE3) and adenocarcinoma (TE7). Following cell-cycle arrest at G2 phase after oxaliplatin treatment, TE3 cells died via apoptosis and TE7 cells died via mitotic catastrophe. Survivin was inhibited more in TE7 cells compared with TE3 cells, but inhibition of survivin using small interfering RNA induced mitotic catastrophe in both cell lines. Further investigations indicated that survivin promoter activity was also inhibited by oxaliplatin. Among mitotic catastrophe-associated proteins, 14-3-3σ was decreased in TE7 cells; no evident changes were observed for aurora kinases. Oxaliplatin-induced apoptosis in the TE3 cells was caspase dependent. However, downregulation of Bad, Bid, Puma, and Noxa, lack of cytochrome c release, and limited loss of mitochondrial membrane potential in early phase indicated possible initiation by pathways other than the mitochondrial pathway. Mechanistic studies showed that downregulation of survivin by oxaliplatin in TE7 cells was partially due to the proteasome-mediated protein degradation pathway and partially due to the downregulation of Sp1 transcription factor. Similar results were obtained for another gastric adenocarcinoma cell line, MKN45, in which survivin was previously shown to be inhibited by oxaliplatin. These data indicate that survivin may be a key target for oxaliplatin. The ability of oxaliplatin to induce different modes of cell death may contribute to its efficacy in esophageal cancer.

UR - http://www.scopus.com/inward/record.url?scp=36949016065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36949016065&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2007.00637.x

DO - 10.1111/j.1349-7006.2007.00637.x

M3 - Article

C2 - 17949450

AN - SCOPUS:36949016065

VL - 99

SP - 129

EP - 139

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 1

ER -